DEF: Alzamend Neuro Seeks Stockholder Approval for Director Elections, Auditor Ratification, Stock Issuance, and Reverse Stock Split

Alzamend Neuro is holding its 2025 Annual Meeting of Stockholders virtually on April 25, 2025, to vote on key proposals including the election of directors, ratification of auditors, approval of a stock conversion, and a potential reverse stock split.

Summary

• Alzamend Neuro, Inc. is holding its 2025 Annual Meeting of Stockholders on April 25, 2025, in a virtual format.
• Stockholders will vote on the election of eight directors, the ratification of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2025, and the approval of the conversion of Series C convertible preferred stock into common stock and warrants for up to $5,000,000, less a 5% discount.
• Additionally, stockholders will vote on approving an amendment to the company's Certificate of Incorporation to effect a reverse stock split of the common stock by a ratio of not less than one-for-two and not more than one-for-ten, at any time prior to April 24, 2026.
• The Board of Directors recommends voting 'FOR' all proposals.
• The record date for determining stockholders eligible to vote at the Annual Meeting was March 13, 2025.
• The company is using a virtual meeting format to provide expanded access, improved communication, and cost savings for stockholders and the company.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily presenting information about the upcoming annual meeting and proposals for stockholder vote. The need for a reverse stock split and additional financing suggests some financial challenges, but the overall sentiment is balanced.

Positives

• The virtual meeting format aims to provide expanded access, improved communication, and cost savings for stockholders and the company.
• The Board of Directors is actively seeking stockholder input on key decisions.
• The company is addressing Nasdaq listing requirements through the proposed reverse stock split and equity increase.

Negatives

• The reverse stock split, if implemented, could potentially decrease the market capitalization of the common stock.
• The issuance of shares to the Investor pursuant to the terms of the SPEA will have a dilutive effect on our existing stockholders, including the voting power and the economic rights of the existing stockholders.
• The availability for sale of a large amount of shares by the Investor may depress the market price of our Common Stock and, going forward, may impair our ability to raise additional capital through the public sale of our Common Stock.

Risks

• Failure to approve Proposal No. 3 would require the company to seek alternative financing, potentially on less favorable terms.
• The market price of the Common Stock may not increase following the Reverse Stock Split, and could potentially decrease.
• The reverse stock split may result in some stockholders owning odd lots of fewer than 100 shares of Common Stock which may be more difficult to sell.

Future Outlook

The company anticipates needing significant cash financing to conduct planned clinical trials and operations and needs to increase its stockholders' equity for purposes of Nasdaq continued listing requirements.

Management Comments

• Stephan Jackman, Chief Executive Officer, cordially invites stockholders to attend the Annual Meeting and emphasizes the importance of their vote.

Industry Context

The document does not explicitly discuss industry context, but the need to maintain Nasdaq listing compliance and raise capital for clinical trials is a common theme among publicly traded biotech companies.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards.
• Reverse stock splits are a relatively common mechanism for companies to regain compliance with minimum share price requirements of exchanges like Nasdaq, but the specific ratio and terms vary widely based on individual company circumstances.
• The terms of the Series C Preferred Stock conversion and warrant issuance would need to be compared to similar financing transactions by other small-cap biotech companies to assess their relative favorability.

Related Party Transactions

• On January 31, 2024, we entered into a securities purchase agreement with Ault Lending, pursuant to which we agreed to sell to Ault Lending up to 6,000 shares of Series B Preferred Stock and warrants (the Series B Warrants) to purchase up to 600,000 shares of common stock in one or more closings.

Stakeholder Impact

• Approval of the proposals will impact shareholders through potential dilution (Series C conversion) and changes in share price and trading characteristics (reverse stock split).
• Employees may be affected by the company's ability to secure funding for operations and clinical trials.
• The company's ability to maintain its Nasdaq listing is crucial for its long-term viability and impact on all stakeholders.

Next Steps

• Stockholders need to review the Proxy Statement and cast their votes before the Annual Meeting on April 25, 2025.
• The Board of Directors will determine the exact ratio for the reverse stock split, if approved, based on various factors.
• The company will file a Form 8-K with the SEC to announce the final voting results after the Annual Meeting.

Key Dates